64 related articles for article (PubMed ID: 11388739)
1. CD135.
Del Zotto G; Luchetti F; Zamai L
J Biol Regul Homeost Agents; 2001; 15(1):103-6. PubMed ID: 11388739
[No Abstract] [Full Text] [Related]
2. [FLT3/FLK2: a novel member of tyrosine kinase receptor family].
Wen GY; He FC; Su ZZ
Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):165-7. PubMed ID: 9592244
[No Abstract] [Full Text] [Related]
3. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
[TBL] [Abstract][Full Text] [Related]
4. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase.
Rottapel R; Turck CW; Casteran N; Liu X; Birnbaum D; Pawson T; Dubreuil P
Oncogene; 1994 Jun; 9(6):1755-65. PubMed ID: 8183574
[TBL] [Abstract][Full Text] [Related]
5. [Tumor angiogenesis and Flt tyrosine kinase].
Shibuya M
Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1470-6. PubMed ID: 9279070
[No Abstract] [Full Text] [Related]
6. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase.
Maroc N; Rottapel R; Rosnet O; Marchetto S; Lavezzi C; Mannoni P; Birnbaum D; Dubreuil P
Oncogene; 1993 Apr; 8(4):909-18. PubMed ID: 8384358
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for the PI3' kinase.
Casteran N; Rottapel R; Beslu N; Lecocq E; Birnbaum D; Dubreuil P
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):443-56. PubMed ID: 7920189
[TBL] [Abstract][Full Text] [Related]
8. Fms-like tyrosine kinase 3 catalytic domain can transduce a proliferative signal in FDC-P1 cells that is qualitatively similar to the signal delivered by c-Fms.
Rossner MT; McArthur GA; Allen JD; Metcalf D
Cell Growth Differ; 1994 May; 5(5):549-55. PubMed ID: 8049161
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene.
Lyman SD; James L; Zappone J; Sleath PR; Beckmann MP; Bird T
Oncogene; 1993 Apr; 8(4):815-22. PubMed ID: 7681159
[TBL] [Abstract][Full Text] [Related]
10. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic receptors of class III receptor-type tyrosine kinases.
Rosnet O; Birnbaum D
Crit Rev Oncog; 1993; 4(6):595-613. PubMed ID: 7506935
[TBL] [Abstract][Full Text] [Related]
12. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
Kamikura DM; Naujokas MA; Park M
Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product.
Rubin JS; Bottaro DP; Aaronson SA
Biochim Biophys Acta; 1993 Dec; 1155(3):357-71. PubMed ID: 8268192
[No Abstract] [Full Text] [Related]
14. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T
Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
16. [Study on perineural infiltration in bile duct neoplasm--with special reference to the relationship with RET].
Fukuyoshi I
Hokkaido Igaku Zasshi; 2005 Jan; 80(1):21-30. PubMed ID: 15796028
[No Abstract] [Full Text] [Related]
17. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
18. Normal and oncogenic FLT3.
Naoe T; Kiyoi H
Cell Mol Life Sci; 2004 Dec; 61(23):2932-8. PubMed ID: 15583855
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn binding to the Tyr-615 site by enhancing tyrosine kinase activity.
Choi S; Park S
Oncogene; 1999 Sep; 18(39):5413-22. PubMed ID: 10498895
[TBL] [Abstract][Full Text] [Related]
20. [Pathophysiology and treatment of acute myeloid leukemia].
Naoe J
Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
[No Abstract] [Full Text] [Related]
[Next] [New Search]
